Abstract The axillary reverse mapping (ARM) technique has been developed to map and preserve arm lymphatic drainage during axillary lymph node dissection (ALND) and/or sentinel lymph node (SLN) biopsy, thereby minimizing arm lymphedema. However, several problems remain to be resolved in the practical application of this technique. This article presents a review of current knowledge regarding ARM and discusses the practical applicability and relevance of this technique. Identification rates of ARM nodes were insufficient using blue dye. Although this was improved using radioisotopes, radioisotopes alone do not permit visual mapping of ARM lymphatics. Fluorescence imaging may be useful to improve the identification rate of ARM nodes and lymphatics. On the other hand, the ARM nodes may be involved with metastatic foci in patients with extensive axillary lymph node metastases. Moreover, the SLN draining the breast may be the same as the ARM node draining the upper extremity in a minority of patients. These issues represent important drawbacks of the ARM procedure. The success of ARM in reducing lymphedema has not yet been determined. Further studies are needed before this can be accepted as a standard procedure in surgical management of breast cancer.
Introduction
Despite the application of various risk parameters in the molecular age of staging, the axillary lymph node status remains the most important predictor of outcomes in the breast cancer, so it continues to direct therapy. Currently, sentinel lymph node (SLN) biopsy has become a widely accepted method for surgical staging of axillary lymph nodes in breast cancer. This procedure can avoid unnecessary axillary lymph node dissection (ALND) in nodenegative patients, thereby minimizing arm lymphedema. However, node-positive patients who undergo ALND do not benefit from SLN biopsy. Arm lymphedema develops in 7-77% of patients who undergo ALND [1] [2] [3] [4] [5] [6] [7] [8] . Moreover, SLN biopsy does not completely eliminate arm lymphedema. Several cooperative group trials have shown lymphedema rates in approximately the 7% range with SLN biopsy alone [9, 10] .
Recently, the axillary reverse mapping (ARM) technique has been developed to map and preserve arm lymphatic drainage during ALND and/or SLN biopsy [11, 12] . The arm and breast lymphatic drainage can be separated using blue dye or radioisotopes, allowing safe removal of only the lymphatics of the breast and protection of the lymphatic channels draining the upper extremity during ALND or SLN biopsy. The ARM procedure is based on the hypothesis that the lymphatic pathway from the arm is not involved by metastasis of the primary breast cancer.
Nevertheless, the preservation of ARM nodes and/or lymphatics is not always possible. Several problems remain to be resolved in the practical use of this technique including: (a) insufficient identification rates of the ARM nodes and/or lymphatics as well as a persistent blue stain at the site of injection [11, 12] , (b) the ARM nodes may be involved with metastatic foci in patients with axillary lymph node metastases [13] , and (c) the SLN draining the breast may be the same as the ARM node draining the upper extremity in a minority of patients [14] . These issues represent important limitations of the ARM procedure, because it is oncologically unacceptable to preserve a metastatic ARM node in ALND or converged SLN-ARM node in SLN biopsy. This article presents a review of current knowledge regarding ARM in breast cancer, and discusses the practical applicability and relevance of the ARM procedure.
Lymphedema with ALND and SLN biopsy
Axillary lymph node dissection (ALND) ALND remains the standard approach for the surgical management in patients with node-positive breast cancer. However, ALND may be associated with significant morbidity, including postoperative lymphedema of the involved extremity, neuropathy of the arm, and seroma formation [15] . In several clinical trials, arm lymphedema develops in 7-77% of patients undergoing total ALND [1] [2] [3] [4] [5] [6] [7] [8] . Transection of arm lymphatics during ALND most likely results in lymphedema, but the technique of ALND has changed little over the past decade and involves purely anatomical dissection. Traditionally, it has been suggested that overzealous or circumferential dissection of axillary vein increases the risk of arm lymphedema. The risk of arm lymphedema is often presented as an argument against total ALND. Although partial ALND (level I and II) is often advocated [16] , arm lymphedema develops in 2.7-5.0% of patients treated by partial ALND [15] . Since the incidence of lymphedema in patients undergoing total ALND has gradually decreased since the 1970s [17] , there is little difference in morbidity between partial and total ALND. Interruption of lymph channels by partial ALND is as functionally complete as that achieved by total ALND.
Sentinel lymph node (SLN) biopsy
Currently, breast-conserving surgery with SLN biopsy is a standard surgical management of early breast cancer. SLN biopsy is an effective method of assessing axillary nodal status and avoiding unnecessary ALND in patients with node-negative breast cancer, thereby preventing arm lymphedema. However, cooperative group trials have shown lymphedema rates in approximately the 7% range with SLN biopsy alone [9, 10] . Although SLN biopsy has lower morbidity rates than ALND [1] , it does not correct the problem of arm lymphedema. The pathophysiology underlying the development of lymphedema is not clearly understood, but this higher than expected rate of lymphedema may be secondary to disruption of the virtually unknown arm lymphatic drainage during SLN biopsy [18, 19] . There is an increasing demand for an accurate map of the lymphatic vasculature by clinicians attempting to predict cancer spread and to understand the mechanism of lymphedema after ALND or SLN biopsy.
Lymph nodes and lymphatics from the breast and the upper extremity Knowledge of the lymphatic pathway from the breast tissue is essential for the diagnosis and treatment of axillary lymph node metastases in breast cancer surgery. Sappey's classic studies of the lymphatic anatomy of the chest wall are familiar to most physicians. Sappey [20] distinguished a superficial group of lymphatics originating in the skin over the breast (subcutaneous lymphatics) and a deep group draining the mammary gland itself (intramammary lymphatics). The superficial and intramammary lymphatics anastomose extensively in the breast, and flow from the two lymphatic groups moves centrifugally toward the axillary and internal mammary nodes. Particularly, the axillary lymph nodes constitute the major regional drainage site for breast cancer. Sappey [20] reported that the lymphatics of the breast is collected in a subareolar plexus and then drained toward the axilla via lymph-collecting vessels. However, Turner-Warwick [21] observed that lymphatic pathways from the breast drained directly into the axilla without first passing through the subareolar plexus. Thereby, two potential routes of lymphatic connections from the breast parenchyma to the axilla have been suggested: (a) direct lymphatic connections from the breast parenchyma to the axilla and (b) drainage of parenchyma via the subareolar complex into the axillary lymph nodes [22] . This knowledge is important with regard to the optimal blue dye and radioisotope injection site for identifying SLN in breast cancer [22] .
On the other hand, superficial and deep lymphatics from the upper extremity always flow into the axillary lymph nodes [23] . Usually, there is no communication between the superficial and deep lymphatics except in the epitrochlear region [24] . However, the superficial and deep lymphatics differed in that the superficial lymphatics go straight to the axillary lymph nodes, whereas the deep lymphatics first pass through several interval lymph nodes before reaching the axilla. Thereafter, lymphatics pass through several lymph nodes before merging into one vessel to reach the subclavian vein [24] . In the axilla, there are lymphatic interconnections between the lymph nodes draining the upper extremity and the nodes draining the breast [23] .
Axillary reverse mapping (ARM)

Concept of ARM
The concept of ARM is to map the drainage of the arm with blue dye to determine the anatomical variation in these lymphatics and thus have a roadmap for their preservation [19] . If arm lymphedema is caused by cutting axillary lymphatics, then being able to see and identify them would allow them to be preserved. In effect, ''ARM is the reverse of SLN mapping that serves to map and then remove the lymph nodes draining the breast; ARM involves mapping the arm drainage to allow its preservation'' [19] (Fig. 1 ). This procedure is based on the hypothesis that the lymphatic pathway from the arm is not involved by metastasis of the primary breast cancer [25] . However, the preservation of ARM nodes and/or lymphatics is not always possible, because combining oncological radicality with complete lymphatic preservation may be difficult [25] .
On the other hand, the extent of lymphatic channel disruption required to cause clinically significant lymphedema is unknown. However, it has been suggested that identification and preservation of ARM nodes and/or lymphatics are essential for decreasing post-operative lymphedema rates [18] . Boneti et al. [18] observed the development of lymphedema in two of 12 patients in whom the ARM node and/or lymphatics were sacrificed, whereas no lymphedema occurred in patients in whom the ARM node was spared, regardless of whether SLN biopsy alone or ALND was performed. As prevention is the key to avoiding lymphedema [18] , preservation of ARM nodes and/or lymphatics is worthwhile. If ARM can be confirmed to be both effective in preventing lymphedema and to be safe, this technique will become the most important technological advancement since SLN biopsy.
Mapping of ARM node and lymphatics
Mapping by blue dye injection Several investigators have reported feasibility studies of the ARM procedure using blue dye [11, 12, 18, [25] [26] [27] . Thompson et al. [11] injected 2.5 ml of blue dye intradermally or subdermally into the upper inner arm along the medial intramuscular groove of the ipsilateral arm. After injection, the site was massaged and the arm was elevated for 5 min to enhance arm lymphatic drainage. Consequently, blue lymphatics and/or nodes in relation with ARM were identified in 11 of 18 (61%) patients, although no blue lymphatics or nodes were identified in the remaining seven patients. In the same year, Nos et al. [12] identified ARM nodes in 15 of 21 patients (71%) using a similar technique. Subsequently, several investigators identified ARM nodes using blue dye [18, 25, 27] . However, identification rates of ARM nodes using blue dye alone were insufficient, ranging from 61 to 86% [11, 12, 18, 25, 27] (Table 1) , and the blue staining at the injection site may persist for up to 6 months after injection [11] . To use ARM, the surgeons have to use only isotope in the breast in order to use the blue dye in the arm [19] . This would be not acceptable for those surgeons who believe that the blue dye and radioisotope techniques are complementary for identifying SLN [22, 28, 29] .
Mapping by isotope injection
To improve the identification rate of the ARM nodes and to prevent a persistent blue stain at the site of injection, Nos et al. [13] injected an isotope into the web space of the ipsilateral hand. During ALND, the radioactive ARM node was localized above the second intercostal brachial nerve, and then blue dye was injected directly into the node to visualize the efferent ducts constituting the lymphatic ARM chain. Consequently, the ARM nodes were identified in 21 of 23 patients (91%) ( Table 1) . However, this procedure may be somewhat cumbersome and result in longer operating time. Moreover, direct injection into the ARM node using a syringe with high pressure may cause backflow into SLN, thereby increasing the rate of SLN and ARM confluence. On the other hand, Britton et al. [14] injected 99m Tchuman polyclonal immunoglobulin G into the breast to identify SLN and 111 In-human polyclonal immunoglobulin G into the hand to identify ARM nodes. In the specimen of ALND, the ARM nodes were identified postoperatively in all of 15 patients (100%) using a well-scintillation counter (Table 1) . Thus, radioisotope labeling seems to be more sensitive for detecting ARM nodes than use of blue dye alone. Identification rates of ARM nodes were improved by using radioisotope with or without blue dye [13, 14] , although radioisotope alone does not permit the visual mapping of ARM lymphatics [13] .
Mapping by fluorescent imaging
A pilot study has been started to confirm the feasibility of the ARM technique in the Kanazawa Medical University Hospital. In this study, the ARM nodes and/or lymphatics were identified using a fluorescence imaging system (Photo Dynamic Eye; Hamamatsu Photonics, Hamamatsu, Japan) with subdermal injection of indocyanine green (ICG) (Diagnogreen; Daiichi Pharmaceutical, Tokyo, Japan) [30, 31] . A smaller volume of ICG was injected into the forearm to decrease the risk of long-term tattooing.
Consequently, the fluorescent ARM nodes and/or lymphatics were found in seven of eight patients who underwent ALND (two fluorescent nodes, five fluorescent nodes, and lymphatics) [31] (Table 1 ). In 12 patients who underwent SLN biopsy alone, the fluorescent ARM nodes and/or lymphatics were identified in nine patients (75%). In the remaining three patients, the ARM node was not observed in the SLN field, suggesting that the ARM nodes were located in different fields with respect to the SLN area [31] . Thus, the fluorescence imaging technique is useful for detecting lymphatic drainage from the upper extremity, and it also permits differentiation of fluorescent ARM nodes and/or lymphatics from blue and/or hot SLNs [22] .
Mapping of ARM node and lymphatics in the ALND field and the SLN field
Generally, identification of the ARM nodes is not sufficient in patients undergoing SLN biopsy alone [18, 27, 31] . Boneti et al. [18] reported that blue lymphatics draining the arm were visible from the SLN incision, and so were located near or within the SLN field in 56 (42.7%) of 131 patients. Casabona et al. [27] also reported the blue lymphatics draining from the arm in the SLN biopsy field in 27 of 72 patients (37.5%). In these studies [18, 27] as well as our previous study [31] , a difference was observed in the identification rate of ARM nodes and/or lymphatics in ALND axillary lymph node dissection, ARM axillary reverse mapping, SLN sentinel lymph node the ALND field and in the SLN field (Table 1 ). This may be because the majority of lymphatics draining the arm are anatomically located deeper than the SLN [27] . This hypothesis is consistent with the higher incidence of lymphedema after ALND than after SLN biopsy [1, [32] [33] [34] .
Preservation of ARM node and lymphatics
Metastases in ARM nodes
The concept of the ARM is based on the hypothesis that the lymphatic pathway from the arm is not involved by metastasis of the primary breast cancer [25] . Boneti et al. [18] and Thompson et al. [11] found no cancer cells in the ARM nodes even when the patients had many positive axillary nodes in the initial series. Subsequently, they preserved the ARM nodes in patients in the later series. Casabona et al. [27] also reported that all ARM nodes removed during ALND were negative for malignancy.
In a study performed in France by Nos et al. [13] , however, the ARM nodes showed metastatic involvement in three of 21 patients with N0-3 (14%). Similarly in a study of Noguchi et al. [31] , the ARM nodes were positive in three (38%) of eight patients with a clinically positive node or positive SLN. Although metastatic involvement of the ARM node is found in these small studies, it is not clear in a larger series where and how often the ARM nodes are involved in patients at high risk of axillary lymph node involvement.
There are two possible explanations for the involvement of the ARM nodes with metastasis [13] . The first explanation is related to the natural progression of metastatic disease through the nodes of the axilla. Anatomically, there are lymphatic interconnections between ARM nodes draining from the upper extremity and SLN draining from the breast [23] . Therefore, it was suggested that effacement of nodes by the gross tumor may alter the pattern of lymph flow in these patients, allowing metastasis to the ARM nodes. The second explanation is a limitation of the ARM when the ARM nodes are located in the central nodal group. The central nodal group is closely related to the lymphatic drainage of the breast. If arm lymphatics join the common lymphatic pathway draining from the breast when they exit the axillary basin, their preservation would likely be impossible.
Convergence of ARM node and SLN
The SLN is most commonly located in the central nodal group, and it is possible that the ARM nodes are located in the central nodal group. If the SLN draining the breast is the same node as the ARM node draining the upper extremity, it would be difficult to preserve the ARM node at SLN biopsy.
Britton et al. [14] reported that SLN from the breast was the same as the ARM node from the upper extremity in two (13%) of 15 patients, indicating convergence of the two drainage pathways through the same node. In a study of Noguchi et al. [31] , SLN from the breast was the same as the ARM node from the upper extremity in three (21%) of 14 patients [31] . These findings were supported by a recent anatomical description of the lymphatic territories of the upper extremity [35] . If this common lymph node is removed at SLN biopsy, there will be disruption to the lymphatic drainage of the upper extremity and an increased risk of lymphedema, explaining why SLN biopsy does not correct the problem of lymphedema [1, 9, 36] .
Microsurgical lymphatic-venous anastomosis
It is not always possible to preserve ARM nodes and/or lymphatics during ALND or SLN biopsy. Nos et al. [12] reported that the preservation rate of ARM node was only 47%, indicating that preservation of ARM nodes and/or lymphatics is unfeasible in the remaining patients. These patients would have some disruption of the arm lymphatics regardless of the technique used in the axilla. Therefore, Casabona et al. [26, 27] performed microsurgical lymphatic-venous anastomosis using lymphatic collectors coming from the arm and one of the collateral branches of the axillary vein. Lymphatic collectors were introduced inside the vein, and the inferior edge of the lymphatics introduced into the vein lumen acted as valves to avoid backflow of blood into the lymphatics [37] , thus preventing the occurrence of thrombosis. In fact, lymphatic microsurgery techniques have been shown to be effective in the treatment of peripheral lymphedema [37] . To perform lymphaticvenous microanastomosis, however, the ARM lymphatics must be visible and preserved as much as possible during ALND, while maintaining oncological radicality.
On the other hand, postmastectomy radiotherapy is currently accepted as a standard adjuvant treatment in patients with more than four positive axillary nodes [38] [39] [40] . According to the guidelines of the American Society of Clinical Oncology [38] , the chest wall as well as the supraclavicular region should be irradiated, whereas full axillary radiotherapy should not be performed routinely in patients undergoing ALND. In postmastectomy radiotherapy, the lymphatic-venous microanastomosis in the axilla can be exposed to non-negligible irradiation as tangents with chest wall irradiation. It is well known that the arm lymphedema can be caused by scar formation from surgery and/or radiation therapy. Therefore, long-term follow-up studies are required before we can conclude that this microsurgical technique is effective for prevention of arm lymphedema even after postmastectomy radiotherapy.
Conclusion
Although the goal of the ARM procedure is to reduce the rate of lymphedema in patients requiring AND and/or SLN biopsy, this has yet to be achieved. The ARM nodes may be involved with metastatic foci in some patients with extensive axillary lymph node metastasis. Moreover, the SLN draining the breast is the same node as the ARM node draining the upper extremity in a minority of patients. It is oncologically unacceptable to preserve a metastatic ARM node in ALND or converged SLN-ARM node in SLN biopsy. Therefore, further studies are needed before this technology can be accepted as a standard procedure in the surgical management of breast cancer. On the other hand, microsurgical lymphatic-venous anastomosis may be effective for prevention of arm lymphedema in these patients. However, long-term follow-up studies are required before we can conclude that it is effective for prevention of arm lymphedema even after postmastectomy radiotherapy.
